ABOUT US

  1. Home
  2. About us
  3. Corporate Profile

Corporate Profile

Company Name
Kyowa Pharmaceutical Industry Co., Ltd.
Established
January 29, 1954
Head Office
3-2-4, Nakanoshima, Kita-ku, Osaka, 530-0005, JapanLocations
Officer
Ray Tsunoda, President and Representative Director
Capital
100 million yen
Sales
28.2 billion yen (Fiscal Year ended March 31, 2019)
Employees
640 (As of March 2021)
Business Activities
Development, production, and marketing of pharmaceutical products
Major Shareholder
Unison Capital Partners IV, LPS and Unison Capital Partners IV(F), L.P.

History

Jan, 1954
Founded in Osaka as an OTC company
Mar, 1964
Entered generic drug business, starting manufacture and marketing
Nov, 1989
Established manufacturing plant in Sanda, Hyogo
Apr, 1996
Began strategic focus on psychiatric and neurological pharmaceutical products
Mar, 1997
Established Research Center in Sanda, Hyogo
Jul, 1998
Acquired marketing rights for all generic pharmaceutical products of Boehringer Mannheim K.K. focusing on psychiatric and neurological pharmaceutical products
Oct, 2007
Formed capital alliance with the Lupin Group, with the Lupin Group acquiring majority ownership of company shares
Aug, 2016
Acquired branded product portfolio from Shionogi
Feb, 2017
Entered into an agreement with Astellas Pharma Inc. for exclusive distribution and promotion of Bipresso® Extended Release Tablets
Mar, 2017
Established Tottori Plant in Tottori City
Dec, 2017
Moved Head office to Nakanoshima
Dec, 2019
Severed ties with the Lupin Group (Leveraged buyout of Lupin Group holding by Unison Capital Group)